Inventor · disambiguated record
Bertolt Kreft
Also filed as: KREFT BERTOLT
2 granted patents·18 pending applications·2 citations·filing 2021–2024
36Inventor score
Files withBRIGHT PEAK THERAPEUTICS AG20
Top patents by PatentIndex Score
20 records- 0180US12173062B2Modified TNF-α antibodies and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Granted Dec 24, 2024·2 cites·18 claims
- 0258US12383631B2Immune antigen specific IL-18 immunocytokines and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2023·Granted Aug 12, 2025·0 cites·20 claims
- 0356US2025186594A1Il-18 polypeptides modified with polymersBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0454US2024158537A1Synthetic il-7 and il-7 immunocytokinesBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 0554US2025188166A1Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0654US2025186597A1Targeted immune activation with il-18 immunocytokinesBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0754US2023250181A1Modified checkpoint inhibitors and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 0853US2025197467A1Activatable il-18 immunocytokines and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 0953US2024132563A1Bifunctional cytokine compositionsBRIGHT PEAK THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 1052US2025213705A1Psma targeting ligands and methods of useBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1152US2024424127A1Il-7 polypeptides, immunocytokines comprising same, and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1251US2024376170A1Conditionally activated proteins and methods of useBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1350US2023201365A1Modified cd20 antibodies and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1450US2024417436A1Conditionally activated immunocytokines and methods of useBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1549US2024400614A1Cleavable peptides and methods of use thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 1648US2024116997A1Activatable il-18 polypeptidesBRIGHT PEAK THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 1748US2023181754A1Modified checkpoint inhibitors and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 1848US2023357342A1Modified il-18 polypeptidesBRIGHT PEAK THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 1946US2023201364A1Antibody conjugates and manufacture thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 2045US2022056091A1Modified il-18 polypeptides and uses thereofBRIGHT PEAK THERAPEUTICS AG·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Bertolt Kreft files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →